Aclaris Therapeutics FY Conference Summary Company Overview - Aclaris Therapeutics is a development-stage biotech company focused on large and small molecule therapeutics for immunoinflammatory diseases [3][4] - The company has a strong drug discovery platform developed by former Pfizer employees and a multidisciplinary team experienced in drug development [3] Key Products and Pipeline - **2138**: An oral ITK JAK3 inhibitor, currently in clinical development for atopic dermatitis (AD) [3][6] - **TSLP MAB and TSLP IL4R bispecific construct**: In-licensed biologics from BiOcean, currently in clinical trials [3][4][5] - Aclaris is focusing on atopic dermatitis due to the mechanism of action and competitive landscape [6][7] Clinical Development and Data - The company is actively enrolling patients for the TSLP MAB study in atopic dermatitis, with data expected in the second half of 2026 [7][8] - Aclaris believes their TSLP MAB is 70 times more potent than competitors like Tezspire, which enhances their confidence in achieving positive outcomes [9][10] - Previous studies showed high efficacy with EASI 75 scores of 94% and 88% on IgA, indicating strong potential for their treatments [10] Market Position and Strategy - Aclaris is strategically targeting less competitive indications like atopic dermatitis, while also considering high unmet need areas such as lichen planus and scarring alopecia [14][15] - The company is aware of the competitive intensity in the respiratory indications and has opted to focus on atopic dermatitis for their TSLP MAB [6][7] Future Catalysts - Key upcoming milestones include: - Reporting SAD and MAD data by the end of 2026 - Initiating two Phase 1B studies in moderate to severe asthma and atopic dermatitis [52] - Advancing next-gen ITK into the clinic in the second half of 2026 [52] - The company has a strong cash position of over $167 million, providing a runway until Q3 of 2028 [57] Competitive Landscape - Aclaris acknowledges competition in the ITK space but believes their product's potency and broader applicability will differentiate them [25][30] - The company is monitoring competitor data closely and remains optimistic about their own development trajectory [25][30] Challenges and Considerations - The rising placebo rates in clinical trials pose a challenge, with Aclaris emphasizing the importance of rigorous patient selection to ensure valid results [41][42] - The company is aware of the complexities in dermatology trials and is implementing measures to mitigate variability in patient responses [40][41] Conclusion - Aclaris Therapeutics is positioned for a busy and potentially transformative 2026, with multiple catalysts on the horizon and a focus on innovative treatments for immunoinflammatory diseases [58][59]

Company Overview - Recludix Pharma is a leader in discovering inhibitors for challenging targets related to inflammatory diseases [1][3] - The management team consists of industry veterans with experience from companies like Seagen, Blueprint Medicines, and Lilly [3] - The company has developed a unique drug discovery platform that includes custom DNA-encoded libraries and proprietary screening tools [3] Key Programs - The most advanced program focuses on STAT6 inhibitors, which are relevant for diseases such as atopic dermatitis, asthma, rheumatoid arthritis, and chronic spontaneous urticaria [3] - Recludix has a strategic collaboration with Sanofi for the development and commercialization of a STAT6 inhibitor [3] - The company plans to submit an Investigational New Drug application for its STAT6 inhibitor REX-8756 in 2025 [3] - Recludix is also advancing a potential first-in-class BTK SH2 domain inhibitor targeting B cell or mast cell-driven inflammatory and immune diseases [3] Upcoming Events - Key executives will participate in the Stifel 2025 Virtual Immunology and Inflammation Forum on September 16, 2025 [1] - An overview of the company will be presented during the forum at 3:00 p.m. Eastern Time [1]